Member Info for howdlep

Tyke,

It's dated 13/12 so its pointless now.

You do realise the letter is no longer a letter?

The format changed to as it is now a while back.

Tyke,

The Letter to Shareholders is normally issued via RNS. However, they were unable to do so for reasons. I presume. beyond their control. That said, they should have done so via a tweet instead.

The problem today is they have tweeted a link to the wrong newsletter.

We move on.

Buyers have found a level they wish to accumulate at, which happens to be where FAB previously sold a large chunk at.

Today is just churn. I am not concerned at all.

That's the September newsletter. Should have been:-

https://us20.campaign-archive.com/?u=ee2fb759d033ff87132180f83&id=27194febe7

But remember that FAB's holding has reduced from 5.38% to 5.21% as a result of the loan note conversion and the increase in total shares to 196,976,456.

So we had two 250k delayed buys yesterday, the latter put through after the closing bell. That should bode well for today, particularly if the company RNS or tweet the January newsletter, which was dated 13/12. We must not miss any opportunity to promote the company to both existing and potentially new shareholders.

.....but in the absence of a ready supply of stock (FAB), any sustained buying will ensure a rapid increase in price. Something to bear in mind when the next bit of good news is released. This could come, as has been said, at any moment.

Great to see today's RNS' with both Trevor and Michael converting all loan notes, inclusive of all interest.

Ladies and gentlemen, there are now NO outstanding loan notes to convert!!!

Time for pi's to repurchase positions!!!

A big delayed sell of 1.75m @ 3.5p from yesterday morning at 11.54am, put through after the bell.

We must be due those TR1's on Monday.

The £268,500 2024 loan notes issued on 11 March 2019, include £18,500 from Michael Schmainda, which carry a 6% coupon. So if these are about to be converted at 2p, it would mean an additional 980,500 shares being issued (including interest shares), giving a total in issue of 191,652,042. Given that Kathleen Schmainda already holds 9,108,400 shares (4.78%), their in concert holding would become 10,088,900. This should result in a new increased TR1 for Kathleen from 4.78% to 5.26%. I have assumed here that Michael only holds additional options, rather than actual shares. That may be wrong.

The enlarged total shares in issue would also then mean that the combined FAB/TB concert party holding would be less than 29.99%, so allowing TB to convert more without FAB selling as many.

Note, all these figures assume the increased TR1 for Kathleen comes before the revised one for FAB/TB.

As I have said previously, TB and FAB are acting in concert and so their combined holding must remain under 30%. Otherwise an offer would need to be made for the remaining shares in the company.

With regard to the loan notes, they can be repaid in shares or in money, on or before the expiry date. In both cases, with the associated 6% coupon (interest).

Now one of those loan notes expires in March 24, the other the following year. So the Board have to act now to ensure the March 24 conversion completes asap, otherwise they would have to place to pay back the money. Obviously, the latter is not going to happen.

So whilst this is incredibly frustrating, once it completes then normal services can be resumed. In fact, with a rapidly increasing share price. In the meantime, don't rule out some good news dropping that would cause a big gap up. That would be so annoying for those looking to sell and buy back cheaper. But that is all part of the investment game. Trade in a manner that best suits your circumstances. Good luck one and all.

From 37 min 30 seconds. Good to see Justin surprised:-

https://www.youtube.com/watch?v=EAdUQfpqmps

We have buyers and a tick up. It is now NT for anything above 25k at full.

Zak notes the V shape bull flag above a rising 50 day moving average, so hopefully that is a strong leading indicator of a move up to the top of the rising trend channel from Feb, pointing at 6.5p. This as soon as the end of this month.

https://zakstraderscafe.com/bulletin-board-heroes-january-2/8234/

Indeed it was but did not appear in the RNS:-

https://www.voxmarkets.co.uk/rns/announcement/93151efd-d1cb-4f94-8262-301aac6445cc

Yes indeed re the original June 21 RNS. However, note the additional comment by Michael and of course the reference to AI:-

By eliminating the need to acquire a contrast-enhanced series, IB Zero G means less time in the scanner for patients. And for healthcare systems, IB Zero G provides increased scanner availability and a reduction in gadolinium expense.

“This patent underscores the major impact AI applications can have in healthcare,” said Michael Schmainda, CEO of IB. “IB Zero G has the potential to significantly disrupt routine clinical workflows on a global basis and help millions of patients receive higher quality and safer MR exams,” Schmainda added.

Https://appliedradiology.com/articles/patent-awarded-to-imaging-biometrics-for-no-contrast-mri-exams

Here's a summary of the RNS (Regulatory News Service) announcement regarding IQ-AI Ltd's subsidiary, Imaging Biometrics (IB), and the implications of their recent FDA Fast-Track designation for oral gallium maltolate (GaM) in treating glioblastoma (GBM):

Summary of RNS:

Company Involved: Imaging Biometrics, LLC, a subsidiary of IQ-AI Ltd.

Announcement: The U.S. FDA has granted Fast-Track designation to IB's oral gallium maltolate (GaM) for treating adult patients with relapsed or refractory glioblastoma (GBM), IDH-wildtype.

Significance of FDA Decision: Reflects the urgency and unmet medical need in treating GBM. Oral GaM has also received Orphan Drug designation, highlighting its potential in addressing this critical area.

Benefits of Fast-Track Designation: Enables an accelerated review process with the FDA. This involves increased communication and collaboration, aimed at speeding up the development and approval process.

Company's Response: Trevor Brown, CEO of IQ-AI, expressed satisfaction with this milestone and emphasized commitment to working closely with the FDA to fast-track the clinical development of oral GaM.

Implications and Bullet Points:

Accelerated Development and Approval: Fast-Track designation means quicker development and potential approval of oral GaM, which could lead to faster patient access.

Addressing Unmet Medical Needs: GBM is a severe and currently underserved medical condition. This designation underlines the treatment's importance in filling a significant therapeutic gap.

Increased FDA Interaction: The designation allows for more frequent communication with the FDA, possibly leading to more efficient development processes.

Market Positioning: This milestone enhances the market positioning of IQ-AI and its subsidiary, potentially leading to commercial advantages.

Investor Confidence: Such regulatory milestones can positively impact investor confidence, reflecting the potential success and viability of the treatment.

Enhanced Corporate Reputation: Receiving Fast-Track status boosts the company's reputation in the biotech and pharmaceutical industry, potentially opening doors for future collaborations and investments.

For the benefit of newbies, FAB (Brown family) are reducing so that Trevor can convert loan notes into shares and stay under a combined holding of just under 30%. Additional volume from this superb RNS, is great news for ALL shareholders.

Thanks for that Max. I use HL.

Interesting